Colorectal clinical trials: what is on the horizon?

被引：1

作者：

Ahn, Daniel H. ^{[1
]}

Goldberg, Richard M. ^{[1
]}

机构：

[1] Ohio State Univ, Ctr Comprehens Canc, Dept Internal Med, Div Med Oncol, 460 W 10th Ave, Columbus, OH 43210 USA

来源：

FUTURE ONCOLOGY | 2016年 / 12卷 / 04期

关键词：

colorectal cancer; immunotherapy; next-generation sequencing; targeted therapy; WILD-TYPE KRAS; MICROSATELLITE INSTABILITY; BRAF MUTATION; OPEN-LABEL; ACQUIRED-RESISTANCE; GENE AMPLIFICATION; CANCER STATISTICS; PLUS IRINOTECAN; RAS MUTATIONS; SOLID TUMORS;

D O I：

10.2217/fon.15.327

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Substantial progress has been made in the treatment of colorectal cancer, where more effective therapies have led to improved outcomes in patients with advanced disease. However, the 5-year overall survival rate remains poor. Genomic sequencing has allowed us to understand that colorectal cancer is a heterogeneous disease, where tumor-specific variants affect the prognosis and outcomes in patients. This has shaped the future directions of treatment and the development of clinical trials, including the incorporation of novel targeted therapies and investigations into the role of immunotherapy in colorectal cancer.

引用

页码：525 / 531

页数：7

共 65 条

[1] Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired [J].

Ahmadzadeh, Mojgan ;

Johnson, Laura A. ;

Heemskerk, Bianca ;

Wunderlich, John R. ;

Dudley, Mark E. ;

White, Donald E. ;

Rosenberg, Steven A. .

BLOOD, 2009, 114 (08) :1537-1544

[2] ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers [J].

Aisner, Dara L. ;

Nguyen, Teresa T. ;

Paskulin, Diego D. ;

Le, Anh T. ;

Haney, Jerry ;

Schulte, Nathan ;

Chionh, Fiona ;

Hardingham, Jenny ;

Mariadason, John ;

Tebbutt, Niall ;

Doebele, Robert C. ;

Weickhardt, Andrew J. ;

Varella-Garcia, Marileila .

MOLECULAR CANCER RESEARCH, 2014, 12 (01) :111-118

[3] Histopathological identification of colon cancer with microsatellite instability [J].

Alexander, J ;

Watanabe, T ;

Wu, TT ;

Rashid, A ;

Li, SA ;

Hamilton, SR .

AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (02) :527-535

[4] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[5]

American Cancer Society, COL CANC

[6]

[Anonymous], 106 ANN M AM ASS CAN

[7]

[Anonymous], J CLIN ONCOL S15S

[8]

[Anonymous], J CLIN ONCOL S5S

[9]

[Anonymous], J CLIN ONCOL

[10]

[Anonymous], J CLIN ONCOL S5S

← 1 2 3 4 5 6 7 →